Ruixuan Jiang

1.3k total citations · 1 hit paper
38 papers, 836 citations indexed

About

Ruixuan Jiang is a scholar working on Economics and Econometrics, Oncology and Molecular Biology. According to data from OpenAlex, Ruixuan Jiang has authored 38 papers receiving a total of 836 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Economics and Econometrics, 11 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Ruixuan Jiang's work include Health Systems, Economic Evaluations, Quality of Life (17 papers), Cutaneous Melanoma Detection and Management (8 papers) and Economic and Environmental Valuation (5 papers). Ruixuan Jiang is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (17 papers), Cutaneous Melanoma Detection and Management (8 papers) and Economic and Environmental Valuation (5 papers). Ruixuan Jiang collaborates with scholars based in United States, Germany and Netherlands. Ruixuan Jiang's co-authors include A. Simon Pickard, Mathieu F. Janssen, Ernest H. Law, James W. Shaw, Kristina S. Boye, Feng Xie, Mark Oppe, Jan J.V. Busschbach, Cynthia L. Gong and Alan Balch and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Ruixuan Jiang

37 papers receiving 824 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

United States Valuation of EQ-5D-5L Health States Using an International Protocol

2019 251 citations A. Simon Pickard, Ernest H. Law et al. Value in Health profile →

Peers

Countries citing papers authored by Ruixuan Jiang

Since Specialization

Citations

This map shows the geographic impact of Ruixuan Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruixuan Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruixuan Jiang more than expected).

Fields of papers citing papers by Ruixuan Jiang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruixuan Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruixuan Jiang. The network helps show where Ruixuan Jiang may publish in the future.

Co-authorship network of co-authors of Ruixuan Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Ruixuan Jiang. A scholar is included among the top collaborators of Ruixuan Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruixuan Jiang. Ruixuan Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Identifying early blood glucose trajectories in sepsis linked to distinct long-term outcomes: a K-means clustering study with external validation 2025 ·Frontiers in Immunology ·Huan Ma, (unknown), (unknown), Ruixuan Jiang, (unknown), Xiao Fang, Ruoxu Dou, Xiangdong Guan, (unknown), (unknown), Changjie Cai	1
2	Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States 2023 ·Advances in Therapy ·(unknown), Arielle G. Bensimon, Ruifeng Xu, Ruixuan Jiang, (unknown), (unknown), Mizuho Fukunaga‐Kalabis, Clemens Krepler	3
3	Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment in Colombia for Melanoma Patients with Lymph Node Involvement After Complete Resection 2023 ·Advances in Therapy ·(unknown), (unknown), Fredy R. S. Gutierrez, (unknown), Shujing Zhang, Shan Jiang, Ruixuan Jiang, (unknown), Praveen Dhankhar, Baanie Sawhney, (unknown), (unknown), (unknown)	3
4	Real-world Clinical Outcomes of Patients with Stage IIB or IIC Cutaneous Melanoma Treated at US Community Oncology Clinics 2022 ·Future Oncology ·Wolfram E. Samlowski, Michelle Silver, (unknown), Shujing Zhang, (unknown), Mizuho Fukunaga‐Kalabis, Clemens Krepler, Ruixuan Jiang	4
5	Systematic literature review and meta-analysis of clinical outcomes and prognostic factors for melanoma brain metastases 2022 ·Frontiers in Oncology ·Xiang‐Lin Tan, (unknown), (unknown), Huilin Tang, (unknown), Jiali Han, Ruixuan Jiang, Scott J. Diede, Irene M. Shui	4
6	EQ-5D-5L measurement properties are superior to EQ-5D-3L across the continuum of health using US value sets 2022 ·Health and Quality of Life Outcomes ·Ruixuan Jiang, Kim Rand, Maja Kuharić, A. Simon Pickard	4
7	Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off 2020 ·Quality of Life Research ·Ruixuan Jiang, James W. Shaw, Axel Mühlbacher, Todd A. Lee, Surrey M. Walton, Thomas Kohlmann, Richard Norman, A. Simon Pickard	23
8	Increasing respondent engagement in composite time trade-off tasks by imposing three minimum trade-offs to improve data quality 2020 ·The European Journal of Health Economics ·Ruixuan Jiang, Thomas Kohlmann, Todd A. Lee, Axel Mühlbacher, James W. Shaw, Surrey M. Walton, A. Simon Pickard	2
9	PNS201 UNITED STATES POPULATION NORMS FOR THE EQ-5D-5L 2020 ·Value in Health ·Ruixuan Jiang, Bas Janssen, A. Simon Pickard	2
10	US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples 2020 ·Quality of Life Research ·Ruixuan Jiang, Mathieu F. Janssen, A. Simon Pickard	145
11	PNS135 ATTITUDES TOWARD DRUG PRICING IN THE US: FINDINGS FROM A SURVEY IN THE GENERAL POPULATION 2019 ·Value in Health ·Ruixuan Jiang, Maja Kuharić, Andrew Thompson, A. Simon Pickard	1
12	Exploring the Internal Structure of the EQ-5D Using Non–Preference-Based Methods 2019 ·Value in Health ·You‐Shan Feng, Ruixuan Jiang, Thomas Kohlmann, A. Simon Pickard	17
13	United States Valuation of EQ-5D-5L Health States Using an International Protocol breakdown → 2019 ·Value in Health ·A. Simon Pickard, Ernest H. Law, Ruixuan Jiang, Eleanor Pullenayegum, James W. Shaw, Feng Xie, Mark Oppe, Kristina S. Boye, Richard H. Chapman, Cynthia L. Gong, Alan Balch, Jan J.V. Busschbach	251
14	Findings from the 2018 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Student Interest Survey 2018 ·Value in Health ·(unknown), (unknown), (unknown), (unknown), Ruixuan Jiang	1
15	Clinical Trajectories, Healthcare Resource Use, and Costs of Diabetic Nephropathy Among Patients with Type 2 Diabetes: A Latent Class Analysis 2018 ·Diabetes Therapy ·Ruixuan Jiang, Ernest H. Law, (unknown), Hongbo Yang, Eric Q. Wu, Raafat Seifeldin	7
16	The Role of Personality in Treatment-Related Outcome Preferences Among Pharmacy Students 2018 ·American Journal of Pharmaceutical Education ·Ernest H. Law, Ruixuan Jiang, Anika Kaczynski, Axel Mühlbacher, A. Simon Pickard	5
17	The societal cost of heroin use disorder in the United States 2017 ·PLoS ONE ·Ruixuan Jiang, In-Young Lee, Todd A. Lee, A. Simon Pickard	40
18	Using Patient-reported Outcomes to Compare Relative Burden of Cancer: EQ-5D and Functional Assessment of Cancer Therapy-General in Eleven Types of Cancer 2016 ·Clinical Therapeutics ·A. Simon Pickard, Ruixuan Jiang, (unknown), Sarah Rosenbloom, David Cella	34
19	A Pharmacogenetics Service Experience for Pharmacy Students, Residents, and Fellows 2013 ·American Journal of Pharmaceutical Education ·Katarzyna Drozda, (unknown), Ruixuan Jiang, (unknown), Shan S. Wong, Shitalben Patel, Edith A. Nutescu, Larisa H. Cavallari	16
20	Selenium and Colorectal Adenoma: Results of a Pooled Analysis 2004 ·JNCI Journal of the National Cancer Institute ·Elizabeth T. Jacobs, Ruixuan Jiang, David S. Alberts, E. Robert Greenberg, Elaine W. Gunter, Margaret R. Karagas, Elaine Lanza, Luke D. Ratnasinghe, Marvin Reid, Arthur Schatzkin, Stephanie A. Smith‐Warner, Kori Wallace, Marı́a Elena Martı́nez	112

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact